06.05.2023Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
05.18.2023OncoResponse Awarded $13 Million in Funding from CPRIT and Raises $14 Million in Added Funds from Investors to Advance Cancer Immunotherapy
01.09.2023Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma